Research

Retinoblastoma Post-Surgery Treatment - Phase III

Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy

Protocol Description

This Phase III Children's Oncology Group study addresses children who have had surgical removal of an eye for treatment of retinoblastoma. The goals are to determine the prevalence of further spread of the cancer as well as success rates related to surgery alone or surgery in conjunction with chemotherapy. From this study doctors hope to determine the best course of treatment and anticipated success rates.

Eligibility Criteria

Eligible candidates include children up to age 6, who have been diagnosed with cancer in one eye and who underwent surgical removal of the eye, called enucleation, within four weeks of enrollment in the study.
Boys: Up to age 6
Girls: Up to age 6

Requirements
Patients considered to be at high risk for further spread of the disease will be treated with intravenous chemotherapy for up to 6 months followed by observation. Those without high-risk histopathologic features will still undergo observation for up to 5 years.
Visits: Number of visits depends on whether patient is considered high-risk or not and the specific course of treatment required.
Duration: 6 months with chemotherapy; participants may be followed for up to 5 years.

Status: Open for Enrollment

Source of Support
Children’s Oncology Group (Study ARET0332)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health